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Abstract
The clinical scenario of acquired cisplatin resistance is considered as a major 
impediment in cervical cancer treatment. Bulky drug-DNA adducts formed by 
cisplatin elicits DNA damage response (DDR) which either subsequently induces 
apoptosis in the cervical cancer cells or enables them to adapt with drug assault by 
invigorating pro-survival molecular cascades. When HPV infected cervical cancer 
cells encounter cisplatin, a complex molecular interaction between deregulated 
tumor suppressors, DNA damage-repair enzymes, and prosurvival molecules get initi-
ated. Ambiguous molecular triggers allow cancer cells to cull apoptosis by opting 
for a survival fate. Overriding of the apoptotic cues by the pro-survival cues renders 
a cisplatin resistant phenotype in the tumor microenvironment. The present review 
undrapes the impact of deregulated signaling nexus formed due to crosstalk of 
the key molecules related to cell survival and apoptosis in orchestrating platinum 
resistance in cervical cancer.
Keywords: HPV, Cervical cancer, Cisplatin resistance, tumor suppressors,  
DNA-damage repair, prosurvival signaling
1. Introduction
Cervical cancer, one of the widespread gynecological cancers, accounts  for 
the maximum deaths amongst women across the globe. As per GLOBOCAN 2018, 
cervical cancer is helmed as the fourth leading cause of mortality and morbidity in 
women after breast and ovarian cancers [1]. As revealed from the data collated by 
World Health Organization (WHO) in 2013, over 85% of the cervical cancer cases 
had surfaced mostly from developing countries with a poor socio-economic back-
drop [2]. Women, owing to lack of awareness, often arrive for seeking medical help 
when the malignant growth of cervix has attained advancement [3].
Infections with a special class of oncogenic DNA viruses called Human Papilloma 
Viruses (HPVs), hailing from the viral family Papillomaviridae, are highly accredited 
for the malignant transformation of cervix. Principally, HPVs are sexually trans-
mitted [4]. On the basis of its carcinogenic potentials, HPVs can be categorized 
as –(i) low-risk HPVs(lr-HPVs) like HPV 6, 11, 42, 43 and 44, and (ii) high-risk 
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HPVs(hr-HPVs)like HPV 16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 and 
70 [4, 5]. Persistent and prevalent infections with hr-HPVs contribute in develop-
ment of cervical cancer alongside other cancers such as the cancer of vagina, vulva, 
penis, anus, head and neck. HPV infections may also give rise to anogenital warts 
and recurrent respiratory papillomatosis [5, 6]. Besides HPVs, several other risk 
factors have been implicated in the etiology of cervical cancer. These mainly include 
long term use of oral contraceptive [7], smoking [8] and infections with Chlamydia 
trachomatis [9].
Cervical cancer progresses through stages of mild dysplasia, moderate dysplasia 
and severe dysplasia to finally aggravate into carcinoma in situ and invasive cancer 
stages [10]. The International Federation of Gynecology and Obstetrics (FIGO) 
classify these developmental grades of cervical intraepithelial neoplasia (CIN) into 
various stages [11, 12]. Rise in the global disease burden is majorly due to treatment 
failure and disease recurrence [13]. The advent of vaccination has allowed for pre-
infection protection [14]. However, lack of cost-effectiveness has limited its use to 
only a certain section of the society, particularly in low income countries like India. 
The therapeutic modality therefore, is skewed to chemotherapy and radiotherapy. 
Stage specific treatment regime is followed for treating cervical cancer [15]. As 
per FIGO conventions, Stage IIB-IVA denotes invasive stages where treatment is 
ensued in forms of conventional modes of chemotherapy and radiotherapy [11]. 
Traditionally, chemotherapy involves use of platinum ligated drugs like cisplatin (cis-
diamminedichloroplatinum; CDDP) [16, 17]. Cisplatin in combination with other 
chemotherapeutics is often employed for treating invasive stages [16]. Patients are 
often subjected to treatment with cisplatin as a ‘radiosensitizer’ prior to radiothera-
peutic intervention in the Concurrent Chemoradiotherapy (CCRT) regime [16]. 
Accordingly, cisplatin is the ‘drug of choice’ to oncologists for treating cervical cancer 
irrespective of its different stages.
In the process of HPV mediated cervical carcinogenesis several molecular 
changes are incited which remodels the metabolic profiles of the cervix [18]. HPV 
induced metabolic paradigm shift bestows the cells with therapy evasive properties. 
Consequentially, neoplastic cells emerge as highly dynamic and evolving entities 
[19]. On encountering drugs, the rewired signaling cascades of the tumor cells 
residing in the cervix get triggered. These eventuate in increased metabolism of 
chemotherapeutics like cisplatin, finally catering in reduced intracellular drug accu-
mulation [20], paving a way for acquired cisplatin resistance. This chapter majorly 
discusses the mechanisms underlying the acquirement of resistance towards 
cisplatin as a result of deregulated activities of tumor suppressors, DNA damage 
repair enzymes and prosurvival molecules, mediated due to HPV infections.
2. HPVs: Integral to etiology of cervical cancer
HPVs are relatively small non-enveloped viruses with a diameter of 55 nm. It 
has a double stranded circular DNA genome which is 8 kb long and is enclosed 
within an icosahedral capsid composed of 72 capsomers [21, 22]. Functionally, the 
HPV genome is regionalized into-i) a non-coding regulatory region called the long 
control region (LCR) or the upper regulatory region (URR), ii) an early region which 
houses E1, E2, E4, E5, E6 and E7 genes, and (iii) a late region which is made up of 
late expressing genes such as L1 and L2 [23]. LCR regulates the process of viral DNA 
replication via controlling the transcription of Open Reading Frames (ORFs). The 
lately transcribed proteins L1 and L2 are the structural proteins of the viral capsid. 
The early genes are dictators of viral replication, transcription, assembly and 
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oncogenesis. Particularly, E6 and E7 are oncogenic and they degrade the cell cycle 
regulators like p53 and pRb to eventuate in cervical carcinoma [23].
These miniscule infectious agents access the cervical epithelial layer through 
crevices or microabrasions that generally forms due to mechanical shock or injury. 
Following entry, HPVs integrate their genome with that of the host to initiate the 
process of malignant transformation of the cervix (Figure 1). The carcinogenesis 
of cervical epithelium begins with the onset of viral lifecycle which initiates with 
viral entry into basal cell layer of the epithelium [24]. The basal cell layer of the 
cervical epidermis enables multiplication and replication of the virus by providing 
them with a suitable microenvironment. Molecules expressed by the basal cells such 
as integrins (α6β1, α6β4), heparan sulphate, and proteoglycans are chemoattractants 
for HPVs [25, 26]. No sooner does the virus enter the basal cells the viral replica-
tion starts but owing to poor copy number the duplication of viral DNA becomes 
non-reproductive. However, as the infection load spreads into the parabasal and 
intermediate layers, which are majorly comprised of semi-differentiated cells or ter-
minally differentiated keratinocytes, DNA copy number increases and productive 
viral replication commences [27]. Meanwhile, the process of cervical carcinogenesis 
gets driven as the virus multiplies and sustains itself in the host system.
Figure 1. 
Host cell hijacking by HPVs. HPVs enter the cervical epithelium through micro abrasions to finally integrate its 
genome into the DNA of the basal cells to promote loss of genomic integrity. Carcinogenesis is accompanied by 
viral multiplication in the cervical epithelium.
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3.  Concomitant molecular changes during cervical carcinogenesis upon 
HPV infection: an escape route to cisplatin therapy
3.1 Onslaught of HPVs deregulates tumor suppressors
HPV mediated neoplastic transformation of cervix kick starts with the abridge-
ment of tumor suppressor functions. An array of experimentations conducted in in 
vitro and in vivo models have successfully established the immortalizing capacities of 
E6 and E7 viral gene products; ensued via degradation of cell cycle controllers like p53 
and pRb [28, 29]. E6 promotes ubiquitin mediated degradation of p53 in assistance 
with E6-associated protein (E6AP), a homolog for MDM-2 expressed in cells infected 
with hr-HPVs [30, 31]. As per reports, E6AP very efficaciously reduces the half-life of 
p53 in HPV infected cervical carcinoma cells, precisely as MDM-2, the conventional 
p53 inhibitor [32]. The guardian of the genome, p53, controls and coordinates the 
major genetic players involved in cell cycle arrest [33]. On top of this, p53 choreographs 
DNA damage repair, and apoptotic events [34]. As the episome formation is success-
fully accomplished by the virus, DNA damage response (DDR) is triggered. Absence of 
functional p53 allows the cervical cells to skip G1-arrest [35]. These functions which are 
central to cell survival and death get violated in the HPV immortalized cervical cells 
owing to reduced p53 levels. A higher E6 level is inversely proportional to cellular p53 
levels [36]. Contrarily, the oncoprotein E7 binds with hypophosphorylated retinoblas-
toma protein (pRb); releasing the growth promoter E2F from the Rb-E2F complex. 
E2F translocate to the nucleus to enable expression of genes that drive the infected cells 
through S-phase of the cell cycle [37]. Cumulative loss of function of both of these 
tumor suppressors enables the infected cells to progress through G1 and S phases even 
with genetic errors. Shortfall of repair processes ultimately paves a way for genomic 
disintegrity to prevail; mediating neoplastic growth. Recent reports suggest that E6 
and E7 intervene into the tumor suppressor activity by recruiting methyl groups on 
their promoter region [38, 39]. These oncogenic viral proteins also methylate cyclinA1 
promoter and deregulate cell cycle progression to mediate tumorigenesis [40].
3.2  Cisplatin insensitivity: a consequence of HPV driven deregulation of tumor 
suppressors
HPV immortalized cervical cancer cells, especially those at the invasive stages, 
are subjected to treatment with platinum-ligated drugs like cisplatin. Following 
its cellular entry, cisplatin transforms into a very strong electrophilic species by 
hydrolytic activation. Such an activated drug generates an electrophilic attack on 
cellular nucleophiles like DNA and results in formation of bulky drug-DNA adducts 
which are beyond repair [41]. Inevitably, cancer cells harboring complex cisplatin 
modified DNA will be arrested in the G1 phase of the cell cycle particularly; due to 
generation of DDR response and subsequent activation of p53. Generation of cispl-
atin-DNA adducts activates Ataxia Telangiectasia Mutated (ATM) vis a vis ATM- and 
Rad3-related (ATR) proteins; culminating into phosphorylation at serine 15 residue 
and stabilization of p53 [42]. ATR along with various other proteins form an axis 
of ATR/CHK2/p53/p21; which ultimately mediates apoptosis [43–46]. Therefore, 
p53 functional status is central to mediation of cisplatin cytotoxicity. This was first 
demonstrated in a study conducted with small-cell lung cancer cells where adeno-
viral delivery of p53 sensitized them to cisplatin and resulted in apoptosis [47]. A 
similar study carried out with ovarian cancer cells, reflected cisplatin induced apop-
totic death upon adenovirus mediated delivery of p53 [48]. This tumor suppressor 
takes up multi-modal routes to facilitate cisplatin-induced cell death. Specifically, 
p53 increases the susceptibility of cancer cells towards cisplatin by degrading FLIP 
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(FLICE-like inhibitory protein) and by binding with the anti-apoptotic mediator 
Bcl-xl to inactivate its function [49, 50]. It further activates other tumor suppressors 
like phosphatase and tensin homolog (PTEN) to shut down PI3K/Akt pathway [51]. 
Sometimes, hyperinduction of p53 can disable AMP-kinase (AMPK) [52]; thereby 
forcing the cancer cells to succumb to cisplatin cytotoxicity.
In HPV infected cells, this entire p53 dictated cell-death inducing pathway is 
compromised owing to functional absence of the tumor suppressors. E6 mediated prior 
degradation of p53 in cervical cancer cells, unprecedentedly makes them tolerant to 
the drug. It has been experimentally demonstrated that p53-Bax signaling axis elicited 
cisplatin induced apoptosis in cervical cancer cells [53]. Even in multiple clinical studies, 
patients retaining wild-type p53 have been found to respond better to platinum based 
chemotherapy [54]. Expression patterns of p53 are predictive of success rate of cisplatin 
treatment in adeno-carcinoma of the uterine cervix [55]. A very recent report has envis-
aged the contribution of p53 in restoring cisplatin sensitivity in CDDP resistant cervical 
cancer cells, particularly during combination treatment with doxorubicin [56].
3.3  HPV mediated impairment of DNA repair machinery: an auto-corrector of 
cisplatin-DNA adducts in cervical cancer
Early genes E1 and E2 drive the process of viral replication in the host by acting 
as an origin recognition factor (ORF) and by imparting helicase [57]. Mostly, the viral 
replication is dependent upon host cell factors, especially those which are involved 
in DNA damage repair pathways [58]. Not only HPVs, but other viruses like hepati-
tis C virus (HCV), Epstein–Barr virus (EBV) and human cytomegalovirus (HCMV) 
concocts the components of DNA damage repair pathway to survive in the host cells 
[59, 60]. HPV, while attempting to integrate its genome into the host cell’s DNA, 
incurs DNA damage that eventually evokes DDR.
The host cell has various repair pathways working in a well-knitted fashion to 
clear off irrelevant mistakes that may arise during the process of DNA replication. 
Some of these include- base excision repair (BER), nucleotide excision repair (NER), 
mismatch repair (MMR), homologous recombination (HR) and non-homologous end 
joining (NHEJ). This machinery actively functions to correct errors incorporated 
in DNA during replication while the cell is gradually traversing through different 
stages of the cell cycle. In instances of assault to DNA architecture hurled as single 
strands or double strand breaks, recruitment of ATM or ATR proteins occur at the 
site of damage. Protein complex comprised of MRN (MRE11-RAD50-NBS1) and 
Tip60 recognizes and recruits these proteins to the site of damage. ATM phosphory-
lates a series of downstream effectors which includes CHK2 and the histone H2A 
(H2AX) to begin with the repair process. For correcting double strand breaks, ATM 
switches over to HR pathway wherein the process of repair is executed by breast 
cancer 1/2 (BRCA1, BRCA2), RAD51 and Partner and Localizer of BRCA2 (PALB2) 
molecules [61–63]. In all cases, p53 is found to be the sole dictator of the process as it 
allows repair to occur by arresting cells with erroneous DNA.
Cervical cancer cells infected with hr-HPVs exhibit an upregulation of ATM 
pathway. Throughout the viral lifecycle, ATM response is constitutively kept activated 
owing to phosphorylation of its downstream effectors namely CHK2, NBS1 and 
BRCA1 [62, 63]. Oncogenic early protein E7 along with higher levels of E1 keeps ATM 
activity always at a hike. E1, the ORF while imparting helicase action, forms pseudo-
viral replication origins which initiate the process of DDR by stalling replication forks 
[64, 65]. In high-risk HPV infected cervical cells, the candidates of ATM pathway 
accumulates in the nucleus [66]. The differentiated and undifferentiated cells of 
the cervical epithelium packed with viral genomes also exhibit an upregulation of 
homologous recombination factors [67, 68]. Studies with pharmacological inhibitors 
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have further delineated that ATM remains activated all throughout the viral life-cycle. 
It aids in amplification of viral genome within the differentiated squamous cells [69].
In addition to ATM, HPVs also activate ATR pathway. In HPV infected cells con-
siderably higher levels of ATR-interacting protein or ATRIP and DNA topoisomerase 
2-binding protein 1 or TopBP1 were noted [70]. Multiple studies have shown that in 
cells infected with HPVs has remarkably higher levels of total and phosphorylated 
forms of ATR as well as its downstream effectors, CHK1 [70]. ATM and ATR pathways 
provide the virus with an access to the host replicative machinery. E7 destroys Rb along 
with other related tumor suppressors such as p107 and p130, comprising the family of 
pocket proteins to control the transit of the cells from G1 phase to S-phase. Moreover, 
the released E2F translocates to the nucleus and lead to translational activation of the 
responsive gene, some of which are candidates of DNA damage repair pathways [70].
3.4  HPV seized DNA repair machineries of cervical cancer cells encourages 
acquired Cisplatin resistance
Upregulated activities of DNA damage repair enzymes empower cervical cancer 
cells to quickly repair the cisplatin-DNA adducts. Cisplatin generates intrastrand cross-
links in the DNA to primarily activate nucleotide excision repair (NER) system [71]. It 
has been proposed that NER prevents apoptosis in cisplatin treated cells via activation 
of the members of the ATM pathway followed by its recruitment to the site of damage 
in the DNA. In cervical cancer cells, already activated ATM, immediately starts chew-
ing away drug-DNA adducts; leading to resistance. Over 20 proteins hailing from the 
excision repair cross-complementation group 1 (ERCC1) partake in this process of clear-
ing away the cisplatin-DNA conjugates [72]. At the 5′ site of the bulky cisplatin-DNA 
lesions, ERCC1 gets co-recruited with ERCC4 for excising away DNA-adducts [73]. 
In HCA-1R, a cisplatin resistant cervical cancer cell line, an upregulation of ERCC1 
expression is recognized. Poor cisplatin responders with locally advanced cervical 
squamous cell carcinoma exhibit elevated levels of ERCC1 [74]. ERCC1, therefore, is 
considered as a prognostic biomarker for assessing the survival rate of patients receiv-
ing chemotherapy or CCRT [75, 76]. Another evolutionarily conserved DNA repair 
pathway is Mismatch Repair (MMR) pathway which is highly implicated in cisplatin 
resistance of cervical cancer cells [77]. Amongst the MMR proteins, MutS homolog 2 
(MSH2) has been identified as a contributor of cisplatin resistance in cervical cancer 
cells [78]. Post-meiotic segregation 2 (PMS2), another key member of the MMR system 
is found to be negatively correlated with cervical cisplatin resistance [79–82].
3.5  HPV mediated upregulation of prosurvival signaling cascades: Another 
contributor of cisplatin resistance in cervical cancer
‘Abortive infection’ often referred to active HPV infection, induces the genesis 
of both benign and malignant neoplasms of the cervix [83]. The oncogenic viral 
early gene products initiates cervical carcinogenesis by interacting with the crucial 
prosurvival signaling cascades of the host cell [84]. Besides abrogating p53 and 
pRb functions, HPVs opportunistically modulate four important cellular survival 
pathways by interacting with their upstream effectors such as growth factor receptor, 
notch receptor, Ras along with phosphatidylinositol 3-kinase subunit C (PI3KCA) gene 
which is second messenger activating Akt kinases [85, 86].
3.5.1 Activation of PI3K/Akt signaling
PI3K, particularly was found to be amplified and overtly activated in HPV-
induced cervical cancers [87, 88]. The activation of MAPK/ERK in turn alters 
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transcription of multiple genes that are important for regulation of cell-cycle pro-
gression and cell proliferation. Thus, activation of PI3K begets in Akt activation via 
phosphorylation of the protein in most of the HPV infected cancers. HPV16 E6 acti-
vates receptor protein tyrosine kinases (RTKs) viz. epidermal growth factor receptor 
(EGFR), insulin receptor beta and insulin-like growth factor receptor beta; lying 
upstream of the PI3K/Akt pathway [89]. Activation of Akt results into a series of 
changes in downstream targets. Akt, furthermore can phosphorylate E6 to promote 
its ability to interact with 14–3-3σ, an important protein required for carcinogenic 
progression [90]. A strong association between HPV and surged c-myc expression 
has been evidenced [91–93]. Reportedly, interaction between E6 and c-myc activates 
the enzymatic function of telomerase [94, 95]. In a clinical study, thirty nine out of 
46 cervical cancer specimens evinced phosphorylation of Akt at serine 473 [96]. Akt 
activation was obtained in about, forty-eight percent of stage Ib2-IIb cervical cancer 
patients. HPV infection destabilizes the host genome for which mutations may be 
incurred in PIK3CA gene. Some mutations may be activator mutations accounting 
in Akt hyperactivation in cervical as well as many other HPV-induced cancers [95]. 
Oncogenic mutations and translational amplification of PIK3CA gene, switch on 
PI3K/Akt signaling invigoratingly; driving HPV mediated tumorigenesis.
3.5.2 Activation of mTOR signaling
mTOR kinase functions as a cellular rheostat that amalgamates cellular signal-
ing pathways after sensing growth factor, starvation and energy status. Recently, 
it has been reported that Akt/mTOR activation occurs immediately after exposure 
to HPV16 pseudovirions [96]. mTOR activation is frequently observed in cervical 
squamous cell carcinoma, as well as in most HPV positive head and neck squamous 
cell carcinomas (HNSCC), and oropharyngeal cancers (OPSCC) [93, 97]. HPV 
oncoproteins E7 and E6 can chronologically activate AKT through pRb binding 
and subsequently stimulate mTOR in its complex 1 (mTORC1). These upregulated 
prosurvival signaling molecules lead to a shift in metabolic paradigm of the cancer 
cells. When subjected to cisplatin treatment, the HPV infected cervical cancer cells 
start to metabolize the drug faster than usual. This result in rapid drug efflux and 
eventually lessens intracellular cisplatin levels to orchestrate cisplatin resistance. 
Therefore, most cisplatin resistant cervical cancer cells are often characterized by 
the presence of greater levels of cisplatin efflux pumps [98, 99]. Of late, Li et al. 
showed in their study that in cisplatin resistant cervical cancer cells with upregu-
lated PI3K/Akt pathway, espouses surged levels of Lysosome-associated protein trans-
membrane 4β-35 (LAPTM4B-35) which is another cisplatin exporter [100, 101].
3.5.3 Activation of the Wnt pathway
Nuclear accumulation of β-catenin due to activation of the canonical Wnt/β-
Catenin pathway leads to transcriptional activation of a plethora of proliferative 
genes. This is highly characteristic to HPV16-positive invasive cancers as well 
as early dysplastic lesions [102, 103]. This phenomenon of nuclear accumula-
tion of β-catenin positively correlates with progression of cervical cancer [104]. 
Accordingly, β-catenin was found in higher frequencies within the nucleus of cervi-
cal cancer cell line SiHa (bearing integrated HPV16) and HeLa (bearing integrated 
HPV18) [105]. Lichtig et al. proposed that HPV16 E6 could mechanistically activate 
Wnt/β-catenin pathway in a p53 independent fashion [106]. β-catenin signaling 
pathway exhibited a regulatory activity over acquired resistance to cisplatin via 
upregulation of Bcl-xl [107]. Cisplatin resistance got promoted in neoplasia due to 
shut down of GSK-3β owing to activation of Wnt/β-catenin signaling [108].
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3.5.4 Activation of the Notch pathway
Cellular prosurvival juxtracrine signaling axis involving TGFβ/Notch1 is found 
to be exhilarated in invasive cervical cancer [109]. As the cervical lesions progressed 
from intraepithelial lesions III to microinvasive carcinoma, Notch1 translocated from 
the cytoplasm to the nucleus for ease of function [110]. HPV E6 has been identified as 
an activator of Notch protein in multiple cervical cancer cell lines [111]. Upregulated 
activities of notch protein induce stemness in cervical cancer cells, thereby enabling 
them to evade cisplatin driven cytotoxicity. Inhibition of Notch1was found to revert 
epithelial to mesenchymal transition (EMT); restoring cisplatin sensitivity [112].
3.5.5 Telomerase activation
Viral oncoprotein E6 escalates human telomerase activity by upregulating its 
catalytic subunit hTERT or telomerase reverse transcriptase [113, 114]. E6 on being 
Figure 2. 
Concomitant molecular changes induced by HPV contribute in cisplatin resistance in cervical cancer. The viral 
oncoproteins, particularly E6 and E7 deregulate the crucial molecules involved in cellular metabolism, cell cycle 
progression, DNA damage repair differentiation, survival, and apoptotic death. These changes provide the cervical 
cancer cells to evade cytotoxic cell death upon treatment with cisplatin; leading to acquirement of resistance.
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aided by E6AP binds to the hTERT promoter region to increase its transcriptional 
activity [112]. NFX1–123, an mRNA interacting protein gets positively regulated 
by E6, to maintain higher telomerase expression [115]. E6 upon binding to hTERT 
protein increases telomerase activity via posttranscriptional modifications [116]. 
Telomerase reverse transcriptase was reported to promote cisplatin resistance by 
suppressing apoptosis.
Orchestration of HPV induced signaling nexus in promoting cisplatin resistance 
in cervical cancer is well depicted in Figure 2.
4. Perspective insights
As the virus hijacks the host system, it flips the molecular dynamics according to 
its own survival benefit. As discussed in this review, loss of function of tumor sup-
pressors, magnified activities of DNA repair enzymes and constitutional activation 
prosurvival signaling cascades in the HPV infected cervix, make the situation precari-
ous. The conundrum of drug resistance that arises as a result of these existent changes, 
stymies therapy. Tracking these prior change can aid in planning conventional thera-
peutic regimes. Thus, these molecules can act as valuable prognostic biomarker before 
administration of cisplatin based chemotherapy to cervical cancer patients.
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